Khalil Nazzal

Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

Robert Flisiak, Ewa Janczewska, Marta Wawrzynowicz‐Syczewska et al. · Alimentary Pharmacology & Therapeutics · 2016 · 99 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide

Anne Flint, Khalil Nazzal, Paweł Jagielski et al. · British Journal of Clinical Pharmacology · 2010 · 78 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real‐world experience study

Robert Flisiak, Ewa Janczewska, Mariusz Łucejko et al. · Journal of Viral Hepatitis · 2018 · 26 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Hepatitis A and hepatitis A virus/HIV coinfection in men who have sex with men, Warsaw, Poland, September 2008 to September 2009

Magdalena Monika Dąbrowska, Khalil Nazzal · Eurosurveillance · 2011 · 20 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Expression of programmed cell death protein 1 and T‐cell immunoglobulin‐ and mucin‐domain‐containing molecule‐3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus

Kamila Caraballo Cortés, Sylwia Osuch, Karol Perlejewski et al. · Journal of Viral Hepatitis · 2019 · 15 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17